MYNZ צמיחת רווח למניה בשנה הנוכחית Mainz Biomed NV

The annual EPS trend for Mainz Biomed N.V. (MYNZ) is based on the scaling of the ColoAlert test and growth in kit sales, while 86.30 indicates the current level. Logistic disruptions and sanctions are hindering system certification, creating supply risks. The situation is further complicated by high marketing costs in the US, which limit the expansion of patent-protected European developments.
פילוחים אנליטיים ודוחות נתונים של חברת mainzbiomed.com (MYNZ)

Investors utilize this metric to determine the business expansion premium and evaluate capital management efficiency. The indicator is calculated as the percentage deviation of current earnings per share from the corresponding value of the previous year. By analyzing the growth rate of net income per share compared to last year, one can assess the impact of the German high-tech oncology test production complex on the financial returns of Mainz Biomed N.V. (MYNZ).